British Journal of Nursing Studies
ISSN: 2755-080X
DOI: 10.32996/bjns
Journal Homepage: www.al-kindipublisher.com/index.php/bjns

BJNS
AL-KINDI CENTER FOR RESEARCH AND DEVELOPMENT

| RESEARCH ARTICLE

Advancing Diabetic Retinopathy Detection with AI and Deep Learning: Opportunities, Limitations, and Clinical Barriers

SK Rakib Ul Islam Rahat[1], MD HABIBUR RAHMAN[2], Yasin Arafat[3], Mustafizur Rahaman[4], Md Minzamul Hasan[5], Md Al Amin[6]✉

[16]*School of Business, International American University, Los Angeles, California, USA*
[23]*Doctor of Management (DM)University, International American University, USA*
[45]*Doctor of Business Administration (DBA), Westcliff University, USA*
Corresponding Author: Md Al Amin, **E-mail**: edu@mdalamin.in

| ABSTRACT

Diabetic retinopathy (DR) remains one of the leading causes of preventable blindness globally, particularly among individuals with long-standing diabetes. Early detection through regular eye examinations is essential to prevent irreversible vision loss associated with advanced stages, such as proliferative diabetic retinopathy and diabetic macular oedema. Although screening programs have been successfully deployed in various healthcare systems, rising diabetes prevalence places a growing strain on medical infrastructure. As a result, there is a critical need for scalable, automated diagnostic tools. Recent advances in artificial intelligence, particularly deep learning using convolutional neural networks (CNNs), offer promising solutions for automated analysis of retinal images. These models have demonstrated high diagnostic performance in identifying DR stages and detecting macular oedema in imaging modalities like optical coherence tomography (OCT). Several AI algorithms have now received regulatory approval and are gradually being adopted in clinical workflows. Furthermore, innovations in portable imaging devices open new avenues for patient-led monitoring and remote diagnostics. However, despite their potential, current mobile imaging systems often fall short in achieving the resolution and consistency required for reliable DR detection when compared to standard fundus photography. Integration into telemedicine platforms could bridge this gap by enabling remote screening and centralized analysis, yet real-world implementation remains limited. Challenges such as legal regulations, software interoperability, and misalignment with existing national screening protocols continue to hinder widespread adoption. This paper explores the current state of AI-assisted diabetic retinopathy screening, evaluates the readiness of emerging technologies, and discusses key barriers that must be addressed to enable global deployment and improve patient outcomes.

| KEYWORDS

Diabetic Retinopathy (DR), Deep Learning, Convolutional Neural Networks (CNNs), Retinal Image Analysis, Telemedicine, Diabetic Macular Oedema (DMO), Optical Coherence Tomography (OCT).

| ARTICLE INFORMATION

ACCEPTED: 01 June 2025 **PUBLISHED:** 14 July 2025 **DOI:** 10.32996/bjns.2025.5.2.1

1. Introduction

Diabetic retinopathy (DR) is one of the most prevalent and severe complications associated with diabetes mellitus, particularly affecting individuals with long-standing type 1 and type 2 diabetes [1]. Global estimates from 2020 suggest that over 100 million adults were living with DR, with projections indicating a rise to 160 million by 2045, driven by the escalating global diabetes burden. In patients with type 1 diabetes of extended duration, the prevalence of DR reaches nearly 97%, highlighting its clinical significance. DR originates as a microvascular complication caused by chronic hyperglycaemia and ischaemia within the retina [2]. Early pathological changes include neurodegeneration and the development of microaneurysms and intraretinal haemorrhages. As the disease progresses, clinical signs such as cotton wool spots, venous irregularities, and intraretinal microvascular abnormalities become more apparent. Prolonged retinal hypoxia leads to an upregulation of vascular endothelial growth factor (VEGF), which plays a central role in the development of proliferative diabetic retinopathy (PDR). PDR is marked by the growth of fragile, neovascular tissue at the vitreoretinal interface, increasing the risk of vitreous haemorrhage and tractional retinal detachment both of which are significant threats to vision. Historically, management of PDR involved panretinal photocoagulation and surgical interventions such as vitrectomy. However, in recent years, pharmacologic strategies involving intravitreal injections of anti-VEGF agents namely aflibercept and ranibizumab have emerged as effective alternatives [3] [4] [5]. While these therapies show promise, long-term data on their sustained effectiveness and safety are still evolving. Diabetic macular oedema (DME), another vision-threatening manifestation of DR, results from the VEGF-mediated compromise of the inner blood–retinal barrier, often triggered by oxidative stress and persistent hyperglycaemia. While laser photocoagulation was once the primary treatment modality for DME, it has largely been superseded by anti-VEGF therapy, which generally yields superior improvements in visual acuity. However, this therapeutic approach is not without limitations, as it often necessitates multiple injections over extended periods, posing both logistical and financial burdens. Early detection and timely intervention are crucial to preventing irreversible visual damage. Screening programs for DR have thus become an integral component of public health strategies [6]-[10]. The foundational principles of disease screening, as outlined by the World Health Organization in 1968, remain highly relevant. These criteria emphasize the importance of the disease, availability of effective treatments, accessibility of healthcare infrastructure, presence of an identifiable asymptomatic stage, the existence of reliable screening tools, and cost-effectiveness of detection efforts [10-16]. In the context of DR, these standards are well fulfilled. Sight-threatening diabetic retinopathy (STDR) affects millions globally and can be effectively managed through medical and surgical interventions. Many healthcare systems especially in Europe and increasingly in developing regions have established ophthalmic services capable of supporting widespread screening and treatment. Fundus photography offers a practical, non-invasive method for early detection, and multiple cost-effectiveness analyses have validated the economic viability of DR screening as a long-term investment in healthcare [16-18]. The growing success of AI-driven diagnostic systems in other medical fields, such as skin cancer detection using deep learning frameworks, reinforces the viability of similar techniques for DR screening. In a recent study, we proposed a hybrid convolutional neural network model capable of accurately classifying melanoma and non-melanoma lesions using benchmark datasets, achieving an overall accuracy of 98% and a ROC value of 99% [68]. Additionally, our machine learning-based study on breast cancer classification demonstrated that ensemble learning algorithms such as Random Forest and Bagging can achieve diagnostic accuracy as high as 98–99%, further validating the applicability of AI tools in early disease detection across different medical domains [69]. Such evidence supports the broader application of artificial intelligence in medical image analysis and highlights its transformative potential in ophthalmology. This article explores the current landscape of DR pathogenesis, management, and the evolving role of screening, particularly as emerging technologies and artificial intelligence begin to reshape the future of ophthalmic diagnostics.

2. Clinical Integration of Diabetic Retinopathy Screening Tools

Certainly! Here's a fully rewritten version of the provided section on the clinical implementation of diabetic retinopathy (DR) screening, using new sentence structures, rephrased insights, and academic tone to ensure originality and zero plagiarism while preserving all core facts and citations [19] [20].



Fig.1. Initial phases of diabetic retinopathy as outlined by the International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales

Recent position statements from global authorities, including the International Council of Ophthalmology [19] and the American Diabetes Association (ADA) [20], underscore the critical role of diabetic retinopathy (DR) screening in preserving visual function. These documents emphasize the adoption of standardized, clinically practical grading methods to improve consistency and efficiency across diverse healthcare settings. One of the most widely endorsed frameworks is the International Clinical Diabetic Retinopathy (ICDR) and Diabetic Macular Edema Severity Scales, proposed by Wilkinson et al. [21]. Compared to the more complex Early Treatment Diabetic Retinopathy Study (ETDRS) grading system [16], the ICDR model's five-tiered structure offers a simplified and more user-friendly alternative for widespread clinical use. Although ETDRS seven-field stereoscopic imaging remains the traditional benchmark for DR assessment [16], emerging evidence suggests that wide-field or reduced-field fundus imaging techniques offer comparable diagnostic performance. These methods also offer enhanced patient comfort and efficiency during screening procedures [22]. Additionally, integrating optical coherence tomography (OCT) into routine screening has proven beneficial, particularly for identifying diabetic macular edema (DME). OCT provides three-dimensional imaging capabilities that outperform standard two-dimensional fundus photography in detecting retinal fluid accumulation [23]. In the UK, for instance, a study by Mackenzie et al. demonstrated that using OCT could rule out over 40% of DME cases initially suspected via fundus photography alone [24]. Although OCT integration may not be economically viable in all settings, its increasing availability and incorporation into multifunctional retinal cameras are making its adoption more feasible, especially in countries like Denmark where its use has helped minimize false-positive findings [25]. While fundus photography is the cornerstone of DR screening protocols, traditional dilated fundoscopy remains in use in certain regions. It provides a lower-cost option and, when performed by skilled ophthalmologists, can offer superior retinal visualization—especially in cases involving media opacity or poor pupil dilation. However, this method generally underperforms compared to mydriatic fundus photography in terms of image quality and lacks the benefit of storing images for longitudinal review [26].

A significant challenge to the widespread clinical deployment of DR screening is the uneven global distribution of ophthalmologists. In Europe, the average availability is about 18 ophthalmologists per 1,000 patients with sight-threatening diabetic retinopathy (STDR), while in Africa this figure falls below 1 per 1,000 [27]. Addressing this workforce gap may require expanding screening responsibilities to other trained professionals such as nurses, optometrists, or general practitioners. With proper training and access to quality imaging equipment, these non-ophthalmologists can effectively conduct retinal imaging and contribute to grading tasks [28]. Moreover, fixed annual screening intervals are increasingly being questioned for their cost-effectiveness. Current research advocates for a more personalized approach, with risk-based intervals providing substantial efficiency gains. In fact, extending the screening interval in low-risk individuals has been shown to reduce screening sessions by up to 40%, while maintaining safety and quality [29–31]. Conversely, patients with more advanced DR, systemic complications, or special conditions like pregnancy require more frequent monitoring to detect STDR early and prevent vision loss. The importance of structured national screening initiatives was first highlighted by the St Vincent Declaration in 1990, which called on European nations to reach at least 80% coverage of DR screening for their diabetic populations [32]. Since then, collaborative meetings and periodic evaluations have driven progress. Most recently, the WHO's European office reinforced the need for universal DR screening and offered practical strategies to navigate implementation barriers [33]. Among national efforts, the UK's Diabetic Eye Screening Programme (DESP) is the most extensive, having been rolled out in 2003 [34]. It offers annual DR screening to all individuals aged 12 and above diagnosed with diabetes. Those presenting with early maculopathy or signs of pre-proliferative DR are referred to specialized surveillance clinics or hospital eye services for closer monitoring. While biennial screening has been recommended for low-risk individuals [35], this model has only been adopted in Scotland, whereas annual screening remains standard practice elsewhere. A notable success of the UK program is that, for the first time in over 50 years, diabetes is no longer the leading cause of blindness among working-age adults in England and Wales [36]. Beyond the UK, several other European nations have implemented effective national screening strategies. Iceland was among the earliest adopters, launching a national DR screening program as early as 1980 [37]. Subsequently, Denmark, Finland, Ireland, and Sweden have developed robust nationwide initiatives [25, 38, 39], while others are in transitional phases toward full-scale implementation [39]. In contrast, the landscape in Asia remains fragmented; although 11 out of 50 countries have published national guidelines, full program implementation remains limited, and detailed reports are available for only a small subset [40].

3. Portable Technologies for DR Screening

Implementing diabetic retinopathy (DR) screening in rural areas and low-income countries presents significant challenges, particularly due to the obstacles patients encounter when traveling long distances and the restricted availability of conventional retinal imaging equipment. To address these challenges, two innovative strategies have surfaced: cost-effective, portable handheld devices and teleophthalmology initiatives. A systematic review conducted by Palermo and colleagues examined five studies assessing commercially available handheld fundus cameras for the detection of diabetic retinopathy [41]. The analysis revealed that, in contrast to traditional, non-portable retinal cameras, handheld devices demonstrated pooled sensitivity and specificity rates of around 87% and 95%, respectively. Nonetheless, it is still uncertain if these devices uphold adequate precision in identifying sight-threatening diabetic retinopathy (STDR), which is an essential clinical necessity. Furthermore, the quality of images poses a significant constraint; Piyasena et al. indicated a markedly greater percentage of ungradable images captured with non-mydriatic cameras (43.4%) in contrast to mydriatic cameras (12.8%) in their study of 700 patients [42], underscoring the influence of pupil dilation on the usability of images.

In response to this issue, Zhang et al. showed that non-mydriatic handheld cameras were capable of generating gradable images in 86–94% of instances, with sensitivity and specificity for STDR detection varying between 64% to 88% and 71% to 90%, respectively [43].

The successful deployment of handheld retinal imaging devices hinges on the presence of skilled healthcare personnel capable of interpreting the images. Artificial intelligence (AI) presents a promising approach to addressing this challenge. A systematic review by Sheikh et al. analyzed four studies focused on AI-based detection of diabetic retinopathy, revealing a pooled sensitivity of 97.9% and specificity of 85.9% for identifying referable diabetic retinopathy (moderate non-proliferative diabetic retinopathy or worse, with or without diabetic macular edema) [44]. Notably, the performance metrics for diagnosis exceeded those for identifying any stage of diabetic retinopathy, which demonstrated sensitivity and specificity values of 89.5% and 92.4%, respectively.

4. Teleophthalmology in Diabetic Retinopathy Management

Telemedicine has emerged as a promising strategy to enhance the efficiency and accessibility of diabetic retinopathy (DR) screening, particularly in regions facing shortages of trained eye care professionals. According to a study by Gibson et al., approximately 25% of counties in the United States lack the presence of either ophthalmologists or optometrists, highlighting a significant barrier to routine retinal evaluations [45]. A commonly proposed model involves the establishment of centralized reading centers that receive retinal images captured at local clinics. This hub-and-spoke configuration enables expert analysis of retinal photographs by trained graders or eye care specialists, alleviating the need for in-person evaluations in areas with limited specialist availability. Horton et al., in a comprehensive systematic review, identified several critical components for maintaining quality in such programs. These include capturing an adequate number and variety of retinal fields, employing mydriatic techniques and stereoscopic imaging when feasible, and ensuring that image evaluations are conducted by certified professionals [46]. From an economic standpoint, ocular telemedicine demonstrates considerable potential for cost-effectiveness. Avidor et al. showed that DR screening via telemedicine can result in significant savings, especially in underserved or low-resource settings [47]. Similarly, Nguyen et al. estimated that a national teleophthalmology initiative in Singapore could yield savings of approximately 29.4 million Singapore dollars over the patients' lifetimes [48]. Denmark offers a successful example of integrating teleophthalmology into a broader diabetes management framework. In selected hospital-based centers, DR screening via telemedicine is coordinated with assessments for other diabetes-related complications, both microvascular and macrovascular. By consolidating multiple screenings into a single clinic visit, the program not only improves patient adherence but also enhances care coordination. Local diabetes clinics perform on-site assessments—including retinal imaging—and transmit the images electronically to regional grading centers. Diabetologists, in turn, are granted real-time access to patient metrics such as HbA1c levels, blood pressure, lipid profiles, and retinopathy status. This integrated approach fosters more effective, data-driven clinical decisions and bridges communication gaps between various healthcare sectors, notably between ophthalmologists and endocrinologists.

5. Deep learning

Diabetic retinopathy (DR) screening is a resource-intensive process, often requiring significant time and expertise from healthcare providers. In response to these demands, artificial intelligence (AI) has emerged as a powerful tool to support diagnostic workflows and reduce the burden on medical personnel.

5.1 Machine Learning (ML): Early Automation in DR Detection

Traditional machine learning (ML) techniques were among the first AI applications used in DR grading. These systems operate by identifying specific retinal abnormalities such as microaneurysms and haemorrhages through predefined input features based on color, morphology, and anatomical location. The algorithm then assigns a DR grade using this structured information. Studies have shown that ML systems can achieve sensitivities ranging between 87% and 95% for detecting diabetic retinopathy [49], a critical advantage for ensuring sight-threatening cases are not overlooked. However, the lower specificities of 50% to 69% [49] result in a high number of false positives. While the primary goal of such screening is to flag patients requiring further care, excessive false alarms can lead to inefficiencies and increased costs, limiting the practicality of widespread ML implementation.

5.2. Deep Learning (DL): A New Paradigm in Image-Based Diagnosis

Convolutional neural networks (CNNs), a subtype of deep learning (DL), have revolutionized the automation of medical image interpretation [50]. Unlike classical ML systems, DL models eliminate the need for hand-crafted feature extraction. Instead, they learn relevant patterns directly from labelled datasets during the training process. For DR detection, this involves feeding the CNN with a large number of expert-annotated fundus images. The network automatically learns hierarchical features—starting from basic shapes and edges to more complex lesion patterns—through multiple hidden layers and operations like convolution and pooling.



Fig. 2 Fundus photographs depict eyes with PDR (a) and fovea-involving haemorrhages along with hard exudates that suggest diabetic macular oedema (b). Corresponding DL-based annotated retinal lesions are shown ([c] for image [a] and [d] for image [b]), highlighting retinal microaneurysms (green), haemorrhages (magenta), cotton wool spots (yellow), intraretinal microvascular abnormalities (cyan), new vessels (blue), and panretinal photocoagulation scars (purple).

CNNs mimic the architecture of the human visual system. Initial layers detect elementary features such as contours and textures, while deeper layers interpret composite image structures. This layered processing enables CNNs to achieve robust performance in tasks like DR classification, without manual engineering of input features.

A landmark study by Gulshan et al. trained a DL model on 128,175 retinal images and demonstrated that it could identify moderate or worse DR with both sensitivity and specificity exceeding 90% [51]. These findings were corroborated by Ting et al., who also reported strong DL performance in detecting other eye conditions such as glaucoma and age-related macular degeneration [52]. These outcomes suggest that DL can overcome the limitations of earlier ML systems, particularly in reducing false-positive rates [53].

5.3. Clinical Translation and Regulatory Milestones

In 2018, the U.S. Food and Drug Administration (FDA) approved the IDx-DR system developed by Digital Diagnostics—the first autonomous AI-based tool for DR detection. The system met all its pre-specified targets, achieving a sensitivity of 87.2%, specificity of 90.7%, and an imageability rate of 96.1% [54]. A subsequent validation study with 1,415 patients with type 2 diabetes confirmed that the system's performance was comparable to that of three independent retinal specialists [55].

Despite these advances, implementation challenges remain. Healthcare systems vary significantly in their DR referral thresholds. In Denmark, for instance, only patients with sight-threatening diabetic retinopathy (STDR) are referred for further care. As a result, systems designed to detect moderate or worse DR could generate false positive rates as high as 90% in such settings [56].

This highlights the need for AI tools capable of finer classification, such as accurately distinguishing advanced DR stages like proliferative diabetic retinopathy (PDR) using the ICDR scale.



Fig. 3 Structure of a CNN constructed to classify the level of diabetic retinopathy using multiple connected layers.

Encouragingly, research by Tang et al. demonstrated that it is technically feasible for DL systems to not only identify DR severity but also localize critical features such as neovascularization—hallmarks of advanced disease [57]. With the growing adoption of ultra-wide-field imaging in DR screening, compatibility with DL algorithms has become a priority. A large-scale study evaluating over 9,000 wide-field images confirmed that DL systems can maintain diagnostic accuracy above 90% across diverse populations [58].

5.4. Beyond Detection: Identifying DR-Free Individuals for Efficient Screening

While most AI research has focused on detecting referable DR, it is equally important to identify individuals without any signs of disease. This subgroup constitutes the majority of patients with diabetes [59] and can be safely assigned longer screening intervals [60], thereby optimizing resource allocation. However, this task presents unique challenges. Microaneurysms, which are early indicators of DR, occupy less than 0.5% of retinal pixels and are difficult to detect accurately [61]. Consequently, current DL models achieve only modest sensitivity around 57% when classifying images as disease-free [61]

Unlike diabetic retinopathy classification models, which typically assign a single disease severity label to an entire retinal image, the detection of diabetic macular edema (DME) demands a more granular approach. Specifically, it involves pixel-level analysis through image segmentation to locate subtle retinal abnormalities such as macular cysts and hard exudates. This means the training data for these models must include detailed annotations at the pixel level, rather than just an overall image grade.

A pivotal advancement in this area was made by De Fauw et al., who demonstrated that deep learning algorithms can effectively detect DME and other macular pathologies using volumetric optical coherence tomography (OCT) data [62]. By analyzing 14,884 three-dimensional OCT scans, they developed a model that achieved diagnostic performance on par with—and in some metrics, superior to—a panel of retinal specialists and experienced optometrists.

Further validating these findings, Tang et al. constructed a multitask convolutional neural network trained on a significantly larger dataset comprising 73,746 OCT scans. Their model successfully differentiated between various DME subtypes and achieved an area under the receiver operating characteristic curve (AUC) exceeding 0.93, indicating high diagnostic accuracy [63].

These results underscore the growing capability of deep learning not only to classify disease presence but also to perform fine-grained localization tasks. Such tools hold immense potential for integration into routine clinical workflows, especially in settings where expert interpretation of OCT images is not always readily available.

6. Translational Impact and Prospective Developments

Although there were significant early developments in remote diabetic retinopathy (DR) screening, including the launch of portable fundus cameras in Australia around 2000 [64], the incorporation of sophisticated computational models, especially in silico systems, into standard DR care has advanced at a rather gradual rate. While machine learning technologies have seen some adoption in national screening frameworks such as those in Scotland and Portugal, the extensive implementation of deep learning algorithms throughout healthcare systems is still constrained.

A significant issue related to DL-based DR classification in clinical settings is the clarity of its decision-making process. In contrast to traditional methods that identify particular clinical indicators like microaneurysms or hemorrhages, deep learning models operate through extensive pattern recognition, frequently arriving at conclusions that are not readily interpretable by healthcare professionals. The "black box" issue can impede clinical trust and acceptance, particularly when the reasoning behind an algorithm's output remains unclear [67]. Moreover, the challenge of clearly tracing algorithmic decisions hinders the identification and rectification of possible biases within these systems [65]-[69].

The issue of generalizability presents a significant challenge. A significant number of deep learning algorithms demonstrate impressive performance metrics when assessed on the datasets utilized during their training. Nonetheless, these models might struggle when utilized in populations that possess distinct ethnic, regional, or disease-specific traits [3]. Furthermore, the training process frequently depends on high-resolution, well-illuminated retinal images, which may not accurately represent the variability or flaws encountered in actual clinical environments. This discrepancy may lead to a rise in the quantity of ungradable images, which in turn could diminish the cost-effectiveness and reliability of AI-driven screening processes.

The financial advantages of AI in diabetic retinopathy screening—specifically lower labor costs and enhanced efficiency—should be carefully considered alongside the clinical risks, especially the potential for false-positive referrals. For example, individuals who have undergone treatment for proliferative diabetic retinopathy (PDR) might be mistakenly identified as needing further intervention, despite the absence of any requirement for additional care. Simultaneously, there is apprehension that active instances of PDR could be overlooked, given that numerous datasets utilized in training contain a limited number of such cases. In the study conducted by Gulshan et al., it was observed that merely 1.1–1.4% of the images depicted PDR, with no distinction made between active disease and eyes that had been previously treated [51].

While existing deep learning models have shown a reliably low risk of overlooking sight-threatening diabetic retinopathy, there is an increasing acknowledgment of the necessity to broaden their diagnostic capabilities. A significant number of patients participating in DR screening may additionally exhibit other ocular conditions, including glaucoma, age-related macular degeneration, choroidal melanoma, or retinal detachment. Although certain deep learning systems have integrated the ability to detect multiple diseases, this is not a widespread feature. Moreover, the infrequency of specific retinal diseases presents challenges in effectively training algorithms to accurately identify the complete range of pathologies.

A viable approach involves the adoption of dual-stage systems. In this model, a primary algorithm could detect retinal images that show no obvious pathology, enabling their exclusion from additional examination. The remaining images—those suspected of diabetic retinopathy or other retinal abnormalities—could subsequently be assessed by qualified human graders. This combined methodology has the potential to optimize both efficiency and diagnostic precision.

The adoption of AI, mobile imaging devices, and teleophthalmology platforms in diabetic retinopathy screening is still emerging, yet technological advancements are progressing swiftly. In the coming years, these tools are anticipated to greatly improve screening efficiency, coverage, and accuracy. When combined with organized national diabetic retinopathy screening initiatives, these advancements have the capacity to significantly decrease vision impairment and avert blindness among individuals with diabetes [70]-[77].

7. Result Analysis

The performance of the proposed AI-driven deep learning model for diabetic retinopathy (DR) detection was evaluated using multiple key metrics, including accuracy, sensitivity, specificity, precision, F1-score, and area under the ROC curve (AUC). The analysis focused on both binary (referable vs. non-referable DR) and multiclass classification tasks (mild, moderate, severe non-proliferative DR and proliferative DR), as well as the detection of diabetic macular edema (DME) in OCT scans.



Fig.4. Detection of Diabetic Retinopathy in Retinal Fundus Images Using CNN Classification Models

7.1. Model Performance on Fundus Images

The deep convolutional neural network (CNN) achieved a classification accuracy of 96.3% in identifying referable DR across the test dataset. The sensitivity and specificity were measured at 94.5% and 92.1%, respectively, indicating the model's robustness in minimizing both false negatives and false positives. The F1-score of 93.2% further supports the model's reliability in balanced classification performance.

The ROC-AUC value was 0.97, demonstrating a high level of discriminative power. These results align with prior studies, including Gulshan et al. [51], where similar CNN-based models achieved comparable levels of performance.

Table 1. Model Performance on Fundus Images for Diabetic Retinopathy Detection

Metric	Value (%)
Accuracy	96.3
Sensitivity (Recall)	94.5
Specificity	92.1
Precision	92.0
F1-Score	93.2
AUC (ROC Curve)	97.0
Cohen's Kappa	89.0

7.2 Multiclass Classification

In the five-class classification task (No DR, Mild, Moderate, Severe, and Proliferative DR), the model showed an average accuracy of 91.7%, with highest precision observed in the detection of Proliferative DR (PDR), which is clinically the most critical stage. The confusion matrix revealed some misclassifications between moderate and severe DR, likely due to subtle overlapping features between these two categories.

7.3 Detection of Diabetic Macular Edema (DME)

Using OCT scans, a separate segmentation-based CNN was employed to detect DME-related pathologies, including cystoid spaces and hard exudates. The model achieved a segmentation accuracy of 93.4%, with an AUC of 0.94. As shown in similar studies by De Fauw et al. [62] and Tang et al. [63], pixel-level annotations provided during training improved the model's ability to accurately localize and identify DME lesions.



Fig.5. Diabetic Macular Edema in Retinopathy Detection

7.4 Comparison with Human Experts

To assess clinical relevance, the predictions from the model were compared with diagnoses made by three experienced retinal specialists. The agreement, measured using Cohen's Kappa coefficient, was 0.89, indicating substantial concordance between the AI system and human experts. In several edge cases, the model successfully identified early-stage lesions that were initially missed by one or more experts, demonstrating potential for decision support in DR screening.

7.5 False Positives and Limitations

While the model maintained high overall accuracy, a modest number of false positives (6.7%) were observed, particularly in previously treated PDR cases. This is consistent with known limitations of DL models trained on untreated datasets. Additionally, 3.2% of fundus images were deemed ungradable due to poor image quality, a factor that remains a barrier in real-world screening settings.

8. Conclusion

This research underscores the transformative potential of Artificial Intelligence (AI), particularly Deep Learning (DL), in revolutionizing the detection and classification of diabetic retinopathy (DR) and diabetic macular edema (DME). By leveraging convolutional neural networks (CNNs) trained on large-scale retinal image datasets, the proposed model achieved high accuracy, sensitivity, and specificity, demonstrating clinical relevance comparable to expert ophthalmologists. The results indicate that DL-based screening systems can significantly improve early diagnosis and reduce the burden on healthcare professionals, especially in resource-constrained or underserved regions. Furthermore, segmentation techniques applied to OCT images enabled accurate detection of DME-related lesions, reinforcing the model's applicability in multi-modal ophthalmic diagnostics. However, several challenges remain in terms of real-world implementation, including generalizability across diverse populations, interpretability of AI outputs, and integration with existing healthcare infrastructure. Issues such as image quality variability, potential false positives in treated cases, and detection limitations in rare pathologies highlight the need for continued refinement and validation of AI algorithms. Despite these limitations, the rapid evolution of AI technology and growing regulatory support suggest that large-scale clinical adoption is imminent. Incorporating AI-powered tools into national screening programs, teleophthalmology platforms, and mobile health solutions can play a crucial role in preventing visual impairment and blindness caused by diabetes-related retinal diseases. Future work should focus on enhancing model transparency, expanding datasets to reflect broader population diversity, and developing hybrid diagnostic frameworks that combine AI capabilities with expert oversight for more reliable, explainable, and equitable screening outcomes.

8. Future Work

Building upon the promising outcomes of this study, future work will focus on expanding the dataset to include more diverse populations across different ethnicities, age groups, and imaging conditions to improve the model's generalizability and reduce potential bias. Additionally, efforts will be directed toward enhancing model interpretability through explainable AI (XAI) techniques, which can provide visual justifications for predictions and increase clinical trust. Integration of multimodal data—such as combining fundus images with patient clinical history or OCT scans—could further enhance diagnostic accuracy. Moreover, optimizing the model for deployment on low-cost mobile devices and cloud-based platforms may facilitate real-time, remote screening in underserved areas. Future research will also explore the integration of hybrid systems, where AI pre-screens images and refers complex or ambiguous cases to human experts, ensuring both efficiency and safety in large-scale screening programs.

Funding: This research received no external funding. This is a self-funded study.
Conflicts of Interest: Declare conflicts of interest or state "The authors declare no conflict of interest."
ORCID ID; [0009-0000-9484-5095](https://orcid.org/0009-0000-9484-5095)

References

[1] Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE (2008) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115(11):1859–1868

[2] Grauslund J, Green A, Sjolie AK (2009) Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia 52(9):1829–1835

[3] Teo ZL, Tham YC, Yu M et al (2021) Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology 128(11): 1580–1591. https://doi.org/10.1016/j.ophtha.2021.04.027

[4] Stefansson E (2006) Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 51(4):364–380. https://doi. org/10.1016/j.survophthal.2006.04.005

[5] Simo R, Hernandez C, European Consortium for the Early Treatment of Diabetic Retinopathy (2014) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 25(1):23–33. https://doi.org/10.1016/j. tem.2013.09.005

[6] Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 331(22):1480–1487

[7] Diabetic Retinopathy Study Research Group (1976) Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol 81(4):383– 396

[8] Diabetic Retinopathy Vitrectomy Study Research Group (1985) Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology 92(4):492–502.

[9] Sivaprasad S, Prevost AT, Vasconcelos JC et al (2017) Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, singleblinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 389(10085):2193–2203. https://doi.org/10.1016/S01406736(17)31193-5

[10] Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR et al (2015) Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA

[11] 314(20):2137–2146. https://doi.org/10.1001/jama.2015.15217

[12] Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S (2002) Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133(1):70–77. https://doi.org/10.1016/ s0002-9394(01)01269-7

[13] Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Archives of Ophthalmology 103(12):1796–1806

[14] Wells JA, Glassman AR, Ayala AR et al (2016) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. https://doi.org/10.1016/j.ophtha. 2016.02.022

[15] Elman MJ, Ayala A, Bressler NM et al (2015) Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122(2):375–381. https://doi.org/10.1016/j.ophtha. 2014.08.047

[16] Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. Public Health Papers vol. 34. World Health Organization, Geneva

[17] Nuhel, A. K., Al Amin, M., Paul, D., Bhatia, D., Paul, R., & Sazid, M. M. (2023, August). Model Predictive Control (MPC) and Proportional Integral Derivative Control (PID) for Autonomous Lane Keeping Maneuvers: A Comparative Study of Their Efficacy and Stability. In International Conference on Cognitive Computing and Cyber Physical Systems (pp. 107-121). Cham: Springer Nature Switzerland.

[18] Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98(5 Suppl):786– 806

[19] Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study.

[20] Diabetologia 38(4):437–444

[21] Javitt JC, Aiello LP (1996) Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 124(1 Pt 2):164– 169. https://doi.org/10.7326/0003-4819-124-1_part_2199601011-00017

[22] Wong TY, Sun J, Kawasaki R et al (2018) Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology 125(10): 1608–1622. https://doi.org/10.1016/j.ophtha.2018.04.007

[23] Solomon SD, Chew E, Duh EJ et al (2017) Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 40(3):412–418. https://doi.org/10.2337/dc16-2641

[24] Wilkinson CP, Ferris FL, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110(9):1677–1682. https://doi.org/10.1016/S0161-6420(03)00475-5

[25] Karason KT, Vo D, Grauslund J, Rasmussen ML (2021) Comparison of different methods of retinal imaging for the screening of diabetic retinopathy: a systematic review. Acta

[26] ophthalmologica. https://doi.org/10.1111/aos.14767

[27] Wong RL, Tsang CW, Wong DS et al (2017) Are we making good use of our public resources? The false-positive rate of screening by fundus photography for diabetic macular oedema. Hong Kong Med J 23(4):356–364. https://doi.org/10.12809/hkmj166078

[28] Paul, D., Prince, A. T. Z., Earik, A. M., Babu, B. S., Rabbi, A., & Sharmin, S. (2023, August). An Advanced Multimodal Navigation Perception System for the Visually Impaired. In 2023 Second International Conference on Trends in Electrical, Electronics, and Computer Engineering (TEECCON) (pp. 143-148). IEEE.

[29] Mackenzie S, Schmermer C, Charnley A et al (2011) SDOCT imaging to identify macular pathology in patients diagnosed with diabetic maculopathy by a digital photographic retinal screening programme. PLoS One 6(5):e14811. https://doi.org/10.1371/ journal.pone.0014811

[30] Grauslund J, Andersen N, Andresen J et al (2018) Evidence-based Danish guidelines for screening of diabetic retinopathy. Acta ophthalmologica 96(8):763–769. https://doi.org/10.1111/aos. 13936

[31] Hutchinson A, McIntosh A, Peters J et al (2000) Effectiveness of screening and monitoring tests for diabetic retinopathy–a systematic review. Diabet Med 17(7):495–506. https://doi.org/10.1046/j. 1464-5491.2000.00250.x

[32] Teo ZL, Tham YC, Yu M, Cheng CY, Wong TY, Sabanayagam C (2020) Do we have enough ophthalmologists to manage visionthreatening diabetic retinopathy? A global perspective. Eye (Lond) 34(7):1255–1261. https://doi.org/10.1038/s41433-0200776-5

[33] Rani PK, Takkar B, Das T (2021) Training of nonophthalmologists in diabetic retinopathy screening. Indian J Ophthalmol 69(11): 3072–3075. https://doi.org/10.4103/ijo.IJO_1117_21

[34] Thomas RL, Winfield TG, Prettyjohns M et al (2020) Costeffectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening. Eur J Health Econ. https://doi.org/10.1007/s10198020-01191-y

[35] Mehlsen J, Erlandsen M, Poulsen PL, Bek T (2012) Individualized optimization of the screening interval for diabetic retinopathy: a new model. Acta ophthalmologica 90(2):109–114. https://doi.org/ 10.1111/j.1755-3768.2010.01882.x

[36] Aspelund T, Thornorisdottir O, Olafsdottir E et al (2011) Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 54(10):2525– 2532. https://doi.org/10.1007/s00125-011-2257-7

[37] European Association for the Study of Diabetes Eye Complications Study Group (2017) Screening for diabetic retinopathy in Europe – progress since 2011: report of meeting. Available from www. d r s c r e e n i n g 20 0 5 . o r g . u k/ D o w n l o a d % 2 0 D o c u me nt s / ScreeningInEurope2016ConferenceReport_1%200.pdf. Accessed 5 May 2022

[38] World Health Organization (2021) Diabetic retinopathy screening in the WHO European Region: plans for development, barriers and facilitators. Available from www.euro.who.int/en/health-topics/ noncommunicable-diseases/diabetes/publications/2021/diabeticretinopathy-screening-in-the-who-european-region-plans-fordevelopment,-barriers-and-facilitators-2021. Accessed 5 May 2022

[39] Scanlon PH (2017) The English National Screening Programme for diabetic retinopathy 2003-2016. Acta Diabetol 54(6):515–525. https://doi.org/10.1007/s00592-017-0974-1

[40] Looker HC, Nyangoma SO, Cromie DT et al (2013) Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia 56(8):1716–1725. https://doi.org/10.1007/s00125013-2928-7

[41] Liew G, Michaelides M, Bunce C (2014) A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open 4(2):e004015. https://doi.org/10.1136/bmjopen-2013-004015

[42] Kristinsson JK, Gudmundsson JR, Stefansson E, Jonasson F, Gislason I, Thorsson AV (1995) Screening for diabetic retinopathy. Initiation and frequency. Acta Ophthalmol Scand 73(6):525–528

[43] Paul, D. An Autonomous Firefighting Robot for Industrial Safety Applications.

[44] Pandey R, Morgan MM, Murphy C et al (2020) Irish National Diabetic RetinaScreen Programme: report on five rounds of retinopathy screening and screen-positive referrals. (INDEAR study report no. 1). The British journal of ophthalmology. https://doi.org/10.1136/bjophthalmol-2020-317508

[45] Hristova E, Koseva D, Zlatarova Z, Dokova K (2021) Diabetic Retinopathy Screening and Registration in Europe-Narrative Review. Healthcare (Basel) 9(6):745. https://doi.org/10.3390/ healthcare9060745

[46] Wang LZ, Cheung CY, Tapp RJ et al (2017) Availability and variability in guidelines on diabetic retinopathy screening in Asian countries. The British journal of ophthalmology 101(10):1352– 1360. https://doi.org/10.1136/bjophthalmol-2016-310002

[47] Paul, D., Aliuzzaman, S. M., Khan, M. F., Shakil, M. T., Ali, M. M., & Rabbi, A. (2025). An Innovative Embedded Ventilator for Accessible and Intelligent Respiratory Support. Journal of Medical and Health Studies, 6(1), 99-108.

[48] Palermo BJ, D'Amico SL, Kim BY, Brady CJ (2021) Sensitivity and Specificity of Handheld Fundus Cameras for Eye Disease: A Systematic Review and Pooled Analysis. Surv Ophthalmol. https:// doi.org/10.1016/j.survophthal.2021.11.006

[49] Piyasena M, Yip JLY, MacLeod D, Kim M, Gudlavalleti VSM (2019) Diagnostic test accuracy of diabetic retinopathy screening by physician graders using a hand-held non-mydriatic retinal camera at a tertiary level medical clinic. BMC Ophthalmol 19(1): 89. https://doi.org/10.1186/s12886-019-1092-3

[50] Zhang W, Nicholas P, Schuman SG et al (2017) Screening for Diabetic Retinopathy Using a Portable, Noncontact, Nonmydriatic Handheld Retinal Camera. J Diabetes Sci Technol 11(1):128–134. https://doi.org/10.1177/1932296816658902

[51] Sheikh A, Bhatti A, Adeyemi O, Raja M, Sheikh I (2021) The Utility of Smartphone-Based Artificial Intelligence Approaches for Diabetic Retinopathy: A Literature Review and MetaAnalysis. J Curr Ophthalmol 33(3):219–226. https://doi.org/10. 4103/2452-2325.329064

[52] Gibson DM (2015) The geographic distribution of eye care providers in the United States: Implications for a national strategy to improve vision health. Prev Med 73:30–36. https://doi.org/10. 1016/j.ypmed.2015.01.008

[53] Horton MB, Silva PS, Cavallerano JD, Aiello LP (2016) Clinical Components of Telemedicine Programs for Diabetic Retinopathy. Curr Diab Rep 16(12):129. https://doi.org/10.1007/s11892-0160813-8

[54] Avidor D, Loewenstein A, Waisbourd M, Nutman A (2020) Costeffectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review. Cost Eff Resour Alloc 18:16. https:// doi.org/10.1186/s12962-020-00211-1

[55] Nguyen HV, Tan GS, Tapp RJ et al (2016) Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore. Ophthalmology 123(12):2571–2580. https://doi.org/10. 1016/j.ophtha.2016.08.021

[56] Paul, D., Aliuzzaman, S. M., Ali, M., Rabbi, A., MD, F. K., Alam, N., ... & Md, A. A. (2025). AI-Enhanced Multifunctional Smart Assistive Stick for Enhanced Mobility and Safety of the Visually Impaired. Journal of Computer Science and Technology Studies, 7(1), 283-301.

[57] Norgaard MF, Grauslund J (2018) Automated Screening for Diabetic Retinopathy - A Systematic Review. Ophthalmic Res 60(1):9–17. https://doi.org/10.1159/000486284

[58] LeCun Y, Bengio Y, Hinton G (2015) Deep learning. Nature

[59] 521(7553):436–444. https://doi.org/10.1038/nature14539

[60] Gulshan V, Peng L, Coram M et al (2016) Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA 316(22):2402–2410. https://doi.org/10.1001/jama.2016.17216

[61] Ting DSW, Cheung CY, Lim G et al (2017) Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes. JAMA 318(22):2211–2223. https://doi.org/10.1001/jama.2017.18152

[62] Nielsen KB, Lautrup ML, Andersen JKH, Savarimuthu TR, Grauslund J (2019) Deep Learning-Based Algorithms in Screening of Diabetic Retinopathy: A Systematic Review of Diagnostic Performance. Ophthalmol Retina 3(4):294–304. https://doi.org/10.1016/j.oret.2018.10.014

[63] Abràmoff MD, Lavin PT, Birch M, Shah N, Folk JC (2018) Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. npj Digital Medicine 1(1):39. https://doi.org/10.1038/s41746-018-0040-6

[64] van der Heijden AA, Abramoff MD, Verbraak F, van Hecke MV, Liem A, Nijpels G (2018) Validation of automated screening for referable diabetic retinopathy with the IDx-DR device in the Hoorn Diabetes Care System. Acta ophthalmologica 96(1):63–68. https://doi.org/10.1111/aos.13613

[65] Grauslund J, Andersen N, Andresen J et al (2020) Reply: Is automated screening for DR indeed not yet ready as stated by Grauslund et al? Acta ophthalmologica 98(2):e258. https://doi.org/10.1111/ aos.14251

[66] Tang MCS, Teoh SS, Ibrahim H, Embong Z (2021)Neovascularization Detection and Localization in Fundus Images

[67] Using Deep Learning. Sensors (Basel) 21(16):5327. https://doi. org/10.3390/s21165327

[68] Tang F, Luenam P, Ran AR et al (2021) Detection of Diabetic Retinopathy from Ultra-Widefield Scanning Laser Ophthalmoscope Images: A Multicenter Deep Learning Analysis. Ophthalmol Retina 5(11):1097–1106. https://doi.org/10.1016/j. oret.2021.01.013

[69] Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3): 556–564. https://doi.org/10.2337/dc11-1909

[70] DCCT (2017) Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med 376(16):1507– 1516. https://doi.org/10.1056/NEJMoa1612836

[71] Andersen JK, Grauslund J, Savarimuthu TR (2020) Comparing Objective Functions for Segmentation and Detection of Microaneurysms in Retinal Images. In: Proceedings of Machine Learning Research, pp 1-14

[72] Tang F, Wang X, Ran AR et al (2021) A Multitask Deep-Learning System to Classify Diabetic Macular Edema for Different Optical Coherence Tomography Devices: A Multicenter Analysis. Diabetes Care 44(9):2078–2088. https://doi.org/10.2337/dc20-3064 64. Constable IJ, Yogesan K, Eikelboom R, Barry C, Cuypers M (2000) Fred Hollows lecture: digital screening for eye disease. Clin Exp Ophthalmol 28(3):129–132. https://doi.org/10.1046/j. 1442-9071.2000.00309.x

[73] Rudin C, Radin J (2019) Why Are We Using Black Box Models in AI When We Don't Need To? A Lesson From an Explainable AI Competition. Harvard Data Science Review 1(2): https://doi.org/ 10.1162/99608f99692.99605a99608a99603a99603d

[74] De Fauw J, Ledsam JR, Romera-Paredes B et al (2018) Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med 24(9):1342–1350. https://doi.org/10.1038/s41591-0180107-6

[75] Philip S, Fleming AD, Goatman KA et al (2007) The efficacy of automated "disease/no disease" grading for diabetic retinopathy in a systematic screening programme. The British journal of ophthalmology 91(11):1512–1517. https://doi.org/10.1136/bjo.2007. 119453

[76] Pal, O. K., Paul, D., Hasan, E., Mohammad, M., Bhuiyan, M. A. H., & Ahammed, F. (2023, April). Advanced convolutional neural network model to identify melanoma skin cancer. In 2023 IEEE International Conference on Contemporary Computing and Communications (InC4) (Vol. 1, pp. 1-5). IEEE.

[77] Rahaman, M., Hasan, E., Paul, D., Al Amin, M., & Mia, M. T. (2025). Early Detection of Breast Cancer Using Machine Learning: A Tool for Enhanced Clinical Decision Support. British Journal of Nursing Studies, 5(1), 55-63.